Meiji and Dong-A Socio Initiate P-I Trial for DMB-3115 (biosimilar, ustekinumab)

 Meiji and Dong-A Socio Initiate P-I Trial for DMB-3115 (biosimilar, ustekinumab)

Meiji and Dong-A Socio Initiate P-I Trial for DMB-3115 (biosimilar, ustekinumab)

Shots:

  • The P-I trial involves assessing of DMB-3115 vs reference products (US- and EU-marketed products under the name of Stelara) in healthy volunteers to evaluate its safety, PK and tolerability in Europe
  • In 2011, Meiji and Dong-A signed a joint venture agreement on biosimilars to build DM Bio Limited in Incheon Free Economic Zone and will manufacture DMB-3115
  • DMB-3115 (biosimilar, ustekinumab) is a recombinant immunoglobulin G1 kappa mAb targeting interleukin (IL)-12 and IL-23 while the dosing started on Dec 13, 2019

Click here to read full press release/ article | Ref: Meiji | Image: Signbox

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post